Oramed Pharmaceuticals (ORMP) Other financing activities (2022 - 2026)

Oramed Pharmaceuticals has reported Other financing activities for 5 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities fell 20.69% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 12.93% YoY), and the FY2025 full-year result was $6.0 million, up 49.87% from the prior year.
• Other financing activities for Q1 2026 stood at $1.7 million, down from $2.3 million in the prior quarter.
• The five-year high for Other financing activities was $6.7 million in Q4 2023, with the low at -$8.0 million in Q4 2022.
• Historically, Other financing activities has averaged $451000.0 across 5 years, with a median of $759500.0 in 2025.
• Annual changes were most pronounced in 2023 — Other financing activities tumbled 855.66% — and 2024, when it jumped 1142.28%.
• Oramed Pharmaceuticals' Other financing activities stood at -$8.0 million in 2022, then jumped by 184.41% to $6.7 million in 2023, then plunged by 81.96% to $1.2 million in 2024, then soared by 87.83% to $2.3 million in 2025, then dropped by 23.99% to $1.7 million in 2026.
• The last three Other financing activities figures came in at $1.7 million (Q1 2026), $2.3 million (Q4 2025), and $719000.0 (Q3 2025), per Business Quant data.